Precisis pioneers bioelectronic techniques to target therapeutic currents to specific brain regions
Precisis, a German company, pioneers bioelectronic techniques for precisely targeting therapeutic currents to specific brain regions. AI-based learning models make it possible to activate or inhibit specific brain cells, tailoring treatments to the specific disease.
Their unique thin electrode pad, although outwardly invisible, houses multiple electrodes capable of creating specific electrical fields that penetrate deep into the brain from outside its boundaries. This innovative electrode pad offers consistent support to the patient, acting as a natural safeguard against transmission issues and malfunctions in the targeted brain area. The different modes of current application, that are generated by the implanted device, can be programmed and adjusted form outside by the treating physician, using a tablet that communicates via radiofrequency to the implant. Additionally, the patients themselves can administer therapy via a handheld device that communicates with the implanted system, providing them with a sense of empowerment and control over their disease. The application is very easy. Patients just place the handheld device over the implant and press one button. The Precisis team's unique achievement is to miniaturize bioelectric brain pacemakers, making them so well tolerated that patients accept them as an integral part of their bodies. The research and development teams are well connected with key opinion leading neurologists, with whom they work closely together to develop the most promising electrical treatment for neurological disorders that need treatment alternatives the most. That way it is ensured that the products that are developed meet the market needs.
Precisis is proud to have developed the world’s first minimally invasive brain pacemaker, which is treating designated brain areas without touching the brain. The primary focus is on creating a system that is not only effective but also easy to implant, control, wear, and reverse if necessary. Precisis' most significant achievement to date is the EASEE® system for the treatment of focal epilepsies. Using a minimally invasive procedure, the thin electrode pad is simply placed under the scalp onto the skull, directly over the affected area of the brain but without direct brain contact. With its unique stimulation paradigms, EASEE® is meant to suppress epileptic seizures on the one hand, and on the other hand, it calms the affected brain area over the long term. Both treatment patterns aim to reduce the frequency of upcoming seizures, alleviating the suffering of epilepsy patients.
To see how EASEE® works please click here. EASEE® received CE mark in September 2022 for the treatment of focal epilepsies after two clinical trials showed excellent results in terms of efficacy and safety. The results of the studies are particularly remarkable because they involved "drug refractory" patients who had exhausted various treatments over many years without relief. In these studies, the results indicated a reduction in seizure burden by more than half in over half of the patient group studied, compared to before receiving treatment with EASEE®. Some patients even achieved complete seizure freedom after an initial period. The results were published in JAMA Neurology, click here, to see the full paper.
The most impressive patient is Ibrahim, a patient who received EASEE® during the study, who has been seizure-free for over three years now. After six months of EASEE® treatment, he regained a normal life, going out with friends, earning his drivers license, and living like a typical young adult. He and his family describe EASEE® as “the best invention in the world” since it not only changed Ibrahim’s life but also the lives of the people close to him. You can meet Ibrahim here EASEE® is commercially available in Europe and is generating its first revenues in Germany, Switzerland, and Austria in 2023.
Precisis is passionately driving its commercialization in CE Mark-accepting countries and has plans to enter the US market in the years to come. The company and its CEO MD Dr. Angela Liedler are committed to invest continuously into research and development, aiming to create newer generation devices, to serve market needs, and develop more electrical treatment patterns that would allow to treat other neurological diseases beyond epilepsy.